Pre-Open Stock Movers 07/27: (OGEN) (OBSV) (FFIV) Higher; (BTBT) (MINM) (UPS) Lower (more...)
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Pre-Open Stock Movers:
Oragenics, Inc. (NYSE: OGEN) 54% HIGHER; entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants. The NRC technologies, in combination with the U.S. National Institutes of Health (NIH) elements found in the Company’s Terra CoV-2 vaccine, provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
ObsEva (NASDAQ: OBSV) 22.6% HIGHER; Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatment of preterm labor in the United States.
Bit Digital, Inc. (NASDAQ: BTBT) 13.3% LOWER; gained 110% intra-day on move higher in bitcoin. Bitcoin reversed late in the day on reports Amazon will not accept bitcoin this year.
F5 Networks (NASDAQ: FFIV) 7.8 HIGHER; reported Q3 EPS of $2.76, $0.30 better than the analyst estimate of $2.46. Revenue for the quarter came in at $652 million versus the consensus estimate of $638.14 million. F5 Networks sees Q4 2021 EPS of $2.68-$2.80, versus the consensus of $2.71. F5 Networks sees Q4 2021 revenue of $660-680 million, versus the consensus of $662.1 million.
Minim, Inc. (NASDAQ: MINM) 6.9% LOWER; announced the launch of the Company's proposed public offering of $25 million pursuant to a registration statement filed with the Securities and Exchange Commission (SEC).
Universal Health (NYSE: UHS) 6.7% HIGHER; reported Q2 EPS of $3.76, $1.08 better than the analyst estimate of $2.68. Revenue for the quarter came in at $3.2 billion versus the consensus estimate of $3.01 billion. Announces $1 Billion Increase To Stock Repurchase Program Authorization
UPS (NYSE: UPS) 6.4% LOWER; reported Q2 EPS of $3.06, $0.25 better than the analyst estimate of $2.81. Revenue for the quarter came in at $23.4 billion versus the consensus estimate of $23.24 billion.
Cerecor Inc. (NASDAQ: CERC) 5.4% HIGHER; announced positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (TNFSF14)) monoclonal antibody, in adult patients with moderate to severe Crohn's disease (CD). Crohn’s disease is a disorder affecting as many as 780,000 people in the United States.
ThredUp Inc. (Nasdaq: TDUP) 5% LOWER; announced today the launch of the public offering of 6,424,369 shares of its Class A common stock, consisting of 2,000,000 shares to be issued and sold by thredUP and 4,424,369 shares to be sold by existing stockholders of thredUP.
Sirius XM (NASDAQ: SIRI) 5% HIGHER; reported Q2 EPS of $0.10, $0.03 better than the analyst estimate of $0.07. Revenue for the quarter came in at $2.16 billion versus the consensus estimate of $2.06 billion. Sirius XM sees FY2021 revenue of $8.55 billion, versus the consensus of $8.42 billion.
EVgo, Inc. (NASDAQ: EVGO) 4.6% HIGHER; Evercore ISI initiates coverage with an Outperform rating and a price target of $18.00.
TriNet Group (NYSE: TNET) 4.5% HIGHER; reported Q2 EPS of $1.56, $0.75 better than the analyst estimate of $0.81. Revenue for the quarter came in at $1.1 million versus the consensus estimate of $236.27 million.
Amkor Technology (NASDAQ: AMKR) 4.4% HIGHER; reported Q2 EPS of $0.51, $0.04 better than the analyst estimate of $0.47. Revenue for the quarter came in at $1.41 billion versus the consensus estimate of $1.35 billion. Amkor Technology sees Q3 2021 EPS of $0.60-$0.80, versus the consensus of $0.44. Amkor Technology sees Q3 2021 revenue of $1.65-1.75 billion, versus the consensus of $1.51 billion.
Astra (NASDAQ: ASTR) 3.8% HIGHER; Deutsche Bank initiates coverage with a Buy rating and a price target of $13.00.
General Electric (NYSE: GE) 3.7% HIGHER; reported Q2 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $18.3 billion versus the consensus estimate of $18.13 billion. General Electric sees FY2021 EPS of $0.15-$0.25, versus the consensus of $0.26.
Independence Realty Trust, Inc. (NYSE: IRT) 3.6% LOWER; commencing an underwritten public offering of 14,000,000 shares of common stock.
Tesla (NASDAQ: TSLA) 2.3% HIGHER; reported Q2 EPS of $1.45, $0.49 better than the analyst estimate of $0.96. Revenue for the quarter came in at $11.96 billion versus the consensus estimate of $11.21 billion. Total production was 206,421, versus an expected 201,000. Model 3/Y production was 204,081 and Model S/X production was 2,340.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coinbase (COIN) Applies to Trade Bitcoin, Crypto Futures
- Molecular Data (MKD) Prices $15M Direct Share Offering at $0.38/sh
- Hut 8 Mining Corp (HUT) Prices 17.55M Share Offering at $8.55/sh
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesDeutsche Bank, Stock Buyback, Tesla, Pre-Open Losers, Pre-Open Winners, Bitcoin, Pre Market Movers, Model 3
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!